- Home
- AGIO
as 07-14-2025 4:00pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.4B | IPO Year: | 2013 |
| Target Price: | $58.60 | AVG Volume (30 days): | 615.0K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.41 - $62.58 | Next Earning Date: | 07-31-2025 |
| Revenue: | $37,035,000 | Revenue Growth: | 25.96% |
| Revenue Growth (this year): | 22.3% | Revenue Growth (next year): | 219.19% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burns James William | AGIO | Chief Legal Officer | Jun 24 '25 | Sell | $33.54 | 2,799 | $93,878.46 | 28,650 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
Agios Pharmaceuticals Insider Sold Shares Worth $627,198, According to a Recent SEC Filing
Insider Monkey
a month ago
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential
Insider Monkey
a month ago
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Zacks
a month ago
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Zacks
a month ago
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
GlobeNewswire
2 months ago
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
GlobeNewswire
2 months ago
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Simply Wall St.
2 months ago
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.